The most important factor driving the growth of ophthalmology glaucoma surgery device market is the increasing incidence of eye disorders amongst the aging population. One in three elderly people has some form of eye disease and the risk of severe eye problems has been found to increase significantly with age, particularly in those over the age of 60. People over 75 years of age contribute almost 65% to the total cases of blindness. Moreover, women live longer and have a higher incidence of dry eyes than men.
Changing geographical trends also present considerable opportunities in this market. The changing lifestyles result in consumption of high calorie diets, which lead to increasing prevalence of lifestyle disorders such as diabetes. This causes an increase in the diabetic glaucoma, thus indirectly increasing the rate of visual impairment.
In-depth profiling of the key players have been conducted, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their positions in the global ophthalmology glaucoma surgery device market.
The key players in the ophthalmology glaucoma surgery device market have been identified as Abbott Laboratories (U.S.), Alcon, Inc. (Switzerland), Carl Zeiss Meditec AG (Germany), Nidek Co., Ltd. (U.S.), Lumenis Ltd. (Israel), Ellex Medical Lasers Ltd. (Australia), and Iridex Corporation (U.S.).